General
Preferred name
ensartinib
Synonyms
Ensartinib dihydrochloride ()
X-396 dihydrochloride ()
Ensartinib ()
Ensartinib (dihydrochloride) ()
X-396 ()
X-396 (dihydrochloride) ()
Ensartinib (X-396) dihydrochloride ()
Ensartinib hydrochloride ()
Ensacove ()
X-396 DIHYDROCHLORIDE ()
X-396 HCl ()
P&D ID
PD053793
CAS
1370651-20-9
2137030-98-7
Tags
available
drug
drug candidate
Drug indication
Non-small-cell lung cancer
non-small cell lung carcinoma
Drug Status
approved
investigational
Max Phase
1.0
4.0
First approval
2024
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
DESCRIPTION
Ensartinib dihydrochloride (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
PRICE
283
DESCRIPTION
On december 2024, FDA approved ensartinib to treat non-small cell lung cancer
(PKIDB)
DESCRIPTION
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
10
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugMAP
MedChem Express Bioactive Compound Library
Other bioactive compounds
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
560.15
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
4.72
TPSA
122.47
Fraction CSP3
0.31
Chiral centers
3.0
Largest ring
6.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
ALK
ALK variants
c-Met/HGFR
GOPC-ROS1
TPM3-TRKA
TrkC
Anaplastic lymphoma kinase (ALK)
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Source data
